Production and activation of recombinant hK2 with propeptide mutations resulting in high expression levels.
about
Human tissue kallikrein 5 is a member of a proteolytic cascade pathway involved in seminal clot liquefaction and potentially in prostate cancer progressionExpression and characterization of trypsinogen produced in the human male genital tractStructure-function analyses of human kallikrein-related peptidase 2 establish the 99-loop as master regulator of activity.Novel peptide inhibitors of human kallikrein 2.The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease.Enzymatic properties of human kallikrein-related peptidase 12 (KLK12).Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a (111)In-radiolabelled monoclonal antibody, 11B6.Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers.A Single Glycan at the 99-Loop of Human Kallikrein-related Peptidase 2 Regulates Activation and Enzymatic Activity.Recombinant kallikrein expression: site-specific integration for hK6 production in human cells.Identification of IGFBP-3 fragments generated by KLK2 and prevention of fragmentation by KLK2-inhibiting peptides.Identification of novel peptide inhibitors for human trypsins.Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing.Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer.Activation profiles and regulatory cascades of the human kallikrein-related peptidases.
P2860
Q28300449-C38DC210-5F5B-45D3-B59A-D69FB029FD33Q28345000-20137489-69AA-48DB-96F4-5325CB6AA2ABQ30605285-AB1A1121-839F-4DFC-BAAF-6B5B1B933D4BQ33235991-B3C594E7-C15D-472C-A5A2-087E0C710304Q34447102-124105DB-5B04-4168-8E43-752C4FC0FC15Q34613040-5C0C8D89-2860-498A-8B36-6F257ED47EDAQ35675446-C202D7EA-1FCD-4018-8EF1-F89AE8B90B30Q35748176-49435F61-8A6F-4DFA-92AC-DB546DF80A98Q35861497-66D5969F-455F-4B59-8045-99AED42E9A90Q36442339-656686CD-CFF8-42C4-A871-8A723A098A14Q36519374-0E92D153-9224-445D-8389-87F74A5F9848Q43151753-30D0284A-D6DB-4355-98EA-7174E6AE776DQ43175517-DABCAC2E-4CCD-4F77-A33F-DA7418C36170Q43658907-2A35A480-3C7C-4F23-B737-A3DB14D696F4Q52565489-786AF05B-5DE7-4397-887E-DC641219B90EQ54434829-A7C572FE-9F9C-4291-A3EA-2F53D3F879DF
P2860
Production and activation of recombinant hK2 with propeptide mutations resulting in high expression levels.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Production and activation of r ...... ing in high expression levels.
@en
type
label
Production and activation of r ...... ing in high expression levels.
@en
prefLabel
Production and activation of r ...... ing in high expression levels.
@en
P2093
P2860
P1433
P1476
Production and activation of r ...... ing in high expression levels.
@en
P2093
P2860
P304
P356
10.1046/J.1432-1327.1999.00946.X
P407
P577
1999-12-01T00:00:00Z